Pooled open-label extension of 2 bimekizumab trials in axial spondyloarthritis: of 494 entering the extension, 425 completed week 164, with mean improvements from baseline in spinal pain (−4.3), BASFI (−2.9), fatigue and SF-36 PCS (+12.3); no comparator.
RCTn = 586
Navarro-Compán et al. Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension